Go to content
Koninklijke Philips N.V.

Koninklijke Philips N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 28 nov 2011 - 10:17
Statutaire naam Koninklijke Philips N.V.
Titel Philips receives FDA clearance to market its first whole body PET/MR imaging system in the United States
Bericht Ingenuity TF PET/MR enables clinicians and researchers to open new frontiers and push the bounds of what’s possible in imaging Chicago, United States – Royal Philips Electronics (NYSE: PHG, AEX: PHI) is announcing 510(k) clearance from the Food and Drug Administration (FDA) for the company’s first commercially available whole body positron emission tomography/magnetic resonance (PET/MR) imaging system, the Ingenuity TF PET/MR. This leading edge platform will redefine how medicine is practiced in the future by helping clinicians and researchers investigate novel personalized medicine and treatments for oncology, cardiology and neurology. The system is on display at the 97th annual meeting of the Radiological Society of North America (RSNA), November 27 - December 2. It was previously thought that PET and MR scans were incompatible; however, Philips overcame the enormous technical hurdles, through advances in technology, to create a new class of hybrid imaging that will push the bounds of what’s possible in imaging. The system is designed to provide a state-of-the-art platform well into the future by facilitating the addition of new technologies as they become available.